Pan-90806: Our lead development compound
PanOptica’s lead development compound, PAN-90806 , shows promise as a topical treatment for neovascular age-related macular degeneration (neovascular AMD) and diabetic retinopathy.
PAN-90806 is a potent and selective inhibitor of VEGF, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels). These two pathological processes contribute to the vision loss associated with neovascular AMD. PAN-90806 has completed preclinical proof-of-concept studies in validated animal models relevant to neovascular AMD and diabetic retinopathy. We expect to conduct our first human clinical trial in 2012.
In September 2011, at the annual meeting of the Retina Society in Rome, PanOptica presented preclinical data for PAN-90806 in neonatal mice performed in conjunction with Investigators at the Wilmer Eye Institute at Johns Hopkins University. The study showed that in mice with laser-induced choroidal neovascularization, topically applied PAN-90806 decreased lesion size compared with a control group that received no treatment, an experimental model relevant to neovascular AMD. Similarly, in mice with oxygen-induced ischemic retinopathy, PAN-90806 demonstrated significant reduction of the mean area of pre-retinal neovascularization compared with controls, an experimental model relevant to diabetic retinopathy. These findings add to the growing body of data supporting the development of PAN-90806 as a topical eye drop for the treatment of neovascular AMD, diabetic retinopathy, and potentially diabetic macular edema (DME).
PanOptica plans to develop PAN-90806 through Phase 2 studies, and then seek a biopharmaceutical partner to complete development, regulatory approval, and commercialization of the compound.